Brain serotonin transporter in human methamphetamine users

RationaleResearch on methamphetamine (MA) toxicity primarily focuses on the possibility that some of the behavioural problems in human MA users might be caused by damage to brain dopamine neurones. However, animal data also indicate that MA can damage brain serotonin neurones, and it has been suggested that cognitive problems and aggression in MA users might be explained by serotonergic damage. As information on the brain serotonin system in human MA users is fragmentary, our objective was to determine whether protein levels of serotonin transporter (SERT), a key marker of serotonin neurones, are decreased in brain of chronic MA users.MethodsSERT immunoreactivity was measured using an immunoblotting procedure in autopsied brain of 16 chronic MA users testing positive for the drug in blood and brain and matched controls.ResultsSERT levels were non-significantly decreased (−14% to −33%) in caudate, putamen and thalamus (normal in hippocampus), and, unlike the robust striatal dopamine reduction, there was marked overlap between control and MA user ranges. Concentrations of SERT were significantly decreased (−23% to −39%) in orbitofrontal and occipital cortices (normal in frontopolar and temporal cortices).ConclusionsOur data suggest that MA might modestly damage brain serotonin neurones and/or inhibit SERT protein expression, with cerebral cortex being more affected than sub-cortical regions. The SERT reduction in orbitofrontal cortex complements other data suggesting involvement of this area in MA-related behaviour. Decreased brain SERT could also be related to the clinical finding that treatment with a selective serotonin re-uptake inhibitor might increase relapse to MA.

[1]  Y. Furukawa,et al.  Low striatal serotonin transporter protein in a human polydrug MDMA (ecstasy) user: a case study , 2010, Journal of psychopharmacology.

[2]  Sylvain Houle,et al.  Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? , 2005, Nuclear medicine and biology.

[3]  S. Kish,et al.  Levels of 4-Hydroxynonenal and Malondialdehyde Are Increased in Brain of Human Chronic Users of Methamphetamine , 2006, Journal of Pharmacology and Experimental Therapeutics.

[4]  J S Fowler,et al.  Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. , 2001, The American journal of psychiatry.

[5]  J S Fowler,et al.  Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. , 2001, The American journal of psychiatry.

[6]  Z. Szabo,et al.  Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (±)3,4-methylenedioxymethamphetamine (“ecstasy”) users: relationship to cognitive performance , 2008, Psychopharmacology.

[7]  John Hilton,et al.  Positron emission tomography of striatal serotonin transporters in Parkinson disease. , 2003, Archives of neurology.

[8]  S. Kish.  How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? , 2002, Pharmacology Biochemistry and Behavior.

[9]  Z. Szabo,et al.  Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.

[10]  W. Ling,et al.  Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. , 2006, Drug and alcohol dependence.

[11]  T. Robbins,et al.  Dissociable Deficits in the Decision-Making Cognition of Chronic Amphetamine Abusers, Opiate Abusers, Patients with Focal Damage to Prefrontal Cortex, and Tryptophan-Depleted Normal Volunteers: Evidence for Monoaminergic Mechanisms , 1999, Neuropsychopharmacology.

[12]  B. Way,et al.  Long-Term Methamphetamine Administration in the Vervet Monkey Models Aspects of a Human Exposure: Brain Neurotoxicity and Behavioral Profiles , 2008, Neuropsychopharmacology.

[13]  P. C. Fletcher,et al.  Abnormal frontal activations related to decision-making in current and former amphetamine and opiate dependent individuals , 2005, Psychopharmacology.

[14]  S. Kish,et al.  Marked dissociation between high noradrenaline versus low noradrenaline transporter levels in human nucleus accumbens , 2007, Journal of neurochemistry.

[15]  L. Seiden,et al.  Long-term effects of chronic methamphetamine administration in rhesus monkeys , 1989, Brain Research.

[16]  G. Hanson,et al.  Role of the dopaminergic nigrostriatal pathway in methamphetamine-induced depression of the neostriatal serotonergic system. , 1987, European journal of pharmacology.

[17]  Stephen J. Kish,et al.  Pharmacologic mechanisms of crystal meth , 2008, Canadian Medical Association Journal.

[18]  Marc A Schuckit,et al.  Behavioral and Functional Neuroimaging Evidence for Prefrontal Dysfunction in Methamphetamine-Dependent Subjects , 2002, Neuropsychopharmacology.

[19]  J. M. T. Bittencourt,et al.  An Atlas of the Basal Ganglia, Brain Stem and Spinal Cord based on Myelin-stained Material. H. A. Riley , 1944 .

[20]  G. Di Chiara,et al.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Seiden,et al.  Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain , 1985, Brain Research.

[22]  G. Galloway,et al.  Psychiatric symptoms in methamphetamine users. , 2004, The American journal on addictions.

[23]  Mark Slifstein,et al.  Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  F. Dubeau,et al.  Increased activity of choline acetyltransferase and acetylcholinesterase in actively epileptic human cerebral cortex , 1988, Epilepsy Research.

[25]  M. Iyo,et al.  Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. , 2006, Archives of general psychiatry.

[26]  E. Mundo,et al.  The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. , 2001, Archives of general psychiatry.

[27]  Zsolt Szabo,et al.  Quantitative PET Studies of the Serotonin Transporter in MDMA Users and Controls Using [11C]McN5652 and [11C]DASB , 2005, Neuropsychopharmacology.

[28]  H. Haughey,et al.  The Effects of Methamphetamine on Serotonin Transporter Activity , 2000, Journal of neurochemistry.

[29]  N. Volkow,et al.  Loss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence , 2001, The Journal of Neuroscience.

[30]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[31]  U. McCann,et al.  Severe Dopaminergic Neurotoxicity in Primates After a Common Recreational Dose Regimen of MDMA ("Ecstasy") , 2002, Science.

[32]  Marc A Schuckit,et al.  Decision making by methamphetamine-dependent subjects is associated with error-rate-independent decrease in prefrontal and parietal activation , 2003, Biological Psychiatry.

[33]  Mark Slifstein,et al.  Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652. , 2005, The American journal of psychiatry.

[34]  L. Seiden,et al.  Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. , 1976, Drug and alcohol dependence.

[35]  John Hilton,et al.  Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  J. O'Callaghan,et al.  Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. , 1994, The Journal of pharmacology and experimental therapeutics.

[37]  Alan A. Wilson,et al.  Increased Vesicular Monoamine Transporter Binding during Early Abstinence In Human Methamphetamine Users: Is VMAT2 a Stable Dopamine Neuron Biomarker? , 2008, The Journal of Neuroscience.

[38]  W. van den Brink,et al.  Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [123I]β-CIT SPECT study – preliminary report , 2001, Psychopharmacology.

[39]  A. Levey,et al.  Striatal dopamine nerve terminal markers in human, chronic methamphetamine users , 1996, Nature Medicine.

[40]  D. Murphy,et al.  Exaggerated effect of fluvoxamine in heterozygote serotonin transporter knockout mice , 2003, Journal of neurochemistry.

[41]  P. Fletcher,et al.  Serotonin and drug reward: focus on 5-HT2C receptors. , 2003, European journal of pharmacology.

[42]  S. Kish,et al.  Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users. , 2003, The American journal of psychiatry.

[43]  L. Seiden,et al.  Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study , 1980, Brain Research.

[44]  Morten L Kringelbach,et al.  Methamphetamine Activates Reward Circuitry in Drug Naïve Human Subjects , 2004, Neuropsychopharmacology.

[45]  D. Mash,et al.  Serotonin transporters upregulate with chronic cocaine use , 2000, Journal of Chemical Neuroanatomy.

[46]  John Hilton,et al.  Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions , 2002 .

[47]  Alan A. Wilson,et al.  Brain serotonin transporter binding in non‐depressed patients with Parkinson's disease , 2007, European journal of neurology.

[48]  S. Kish.  Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? , 2003, Advances in neurology.

[49]  T. Su,et al.  Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: A SPECT study , 2007, European Neuropsychopharmacology.

[50]  R. Laverty,et al.  MODIFICATION BY DRUGS OF THE METABOLISM OF 3,4-DIHYDROXYPHENYLETHYLAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE BRAIN. , 1965, British journal of pharmacology and chemotherapy.

[51]  I. Grant,et al.  Neurocognitive Effects of Methamphetamine: A Critical Review and Meta-analysis , 2007, Neuropsychology Review.

[52]  D. Wong,et al.  Reduced Striatal Dopamine Transporter Density in Abstinent Methamphetamine and Methcathinone Users: Evidence from Positron Emission Tomography Studies with [11C]WIN-35,428 , 1998, The Journal of Neuroscience.

[53]  L. Seiden,et al.  Sensitivity changes to dopaminergic agents in fine moto control of rhesus monkeys after repeated methamphetamine administration , 1985, Pharmacology Biochemistry and Behavior.

[54]  S. Kish,et al.  Brief Communications Expedited Publication Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user , 2000 .

[55]  S. Kish,et al.  Why is parkinsonism not a feature of human methamphetamine users? , 2004, Brain : a journal of neurology.

[56]  Joseph P. Huston,et al.  Serotonin and psychostimulant addiction: Focus on 5-HT1A-receptors , 2007, Progress in Neurobiology.

[57]  P. Fletcher,et al.  Depletion of brain serotonin following intra-raphe injections , 1999, Psychopharmacology.

[58]  U. McCann,et al.  Relationship between Temperature, Dopaminergic Neurotoxicity, and Plasma Drug Concentrations in Methamphetamine-Treated Squirrel Monkeys , 2006, Journal of Pharmacology and Experimental Therapeutics.

[59]  R. Guillery,et al.  Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain , 1982, Brain Research.

[60]  U. McCann,et al.  Experimental studies on 3,4-methylenedioxymethamphetamine (MDMA, “ECSTASY”) and its potential to damage brain serotonin neurons , 2009, Neurotoxicity Research.

[61]  D. Wong,et al.  Brain Dopamine Neurotoxicity in Baboons Treated with Doses of Methamphetamine Comparable to Those Recreationally Abused by Humans: Evidence from [11C]WIN-35,428 Positron Emission Tomography Studies and Direct In Vitro Determinations , 1998, The Journal of Neuroscience.

[62]  J. Salamone,et al.  Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits , 2007, Psychopharmacology.

[63]  Junchao Tong,et al.  Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. , 2007, Brain : a journal of neurology.

[64]  M. Molliver,et al.  Immunocytochemical evidence for methamphetamine‐induced serotonergic axon loss in the rat brain , 1991, Synapse.

[65]  R. Albin,et al.  Spared Caudal Brainstem SERT Binding in Early Parkinson's Disease , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[66]  T. Robbins,et al.  Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers , 2006, Psychopharmacology.

[67]  S. Kish,et al.  Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users. , 2001, Forensic science international.

[68]  John Hilton,et al.  as Serotonin Transporter Radioligands Under Various Experimental Conditions , 2002 .

[69]  James Robert Brašić,et al.  Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users , 2008, Synapse.

[70]  Pedro Rosa-Neto,et al.  A-( 11 C)Methyl-L-tryptophan trapping in the orbital and ventral medial prefrontal cortex of suicide , 2006 .

[71]  R. Buchert,et al.  Ecstasy-induced reduction of the availability of the brain serotonin transporter as revealed by [11C](+)McN5652-PET and the multi-linear reference tissue model: loss of transporters or artifact of tracer kinetic modelling? , 2007, Journal of psychopharmacology.

[72]  J. McLean,et al.  Effect of D-Amphetamine on Rat Brain Noradrenaline and Serotonin , 1961, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[73]  Metaphors, Misuse, and Misconceptions , 2003, Science.

[74]  Sung-Cheng Huang,et al.  Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey , 1997, Brain Research.

[75]  C. J. Schmidt,et al.  Methamphetamine‐Induced Depression of Monoamine Synthesis in the Rat: Development of Tolerance , 1985, Journal of neurochemistry.

[76]  L. Seiden,et al.  Altered sensitivity to d-methylamphetamine, apomorphine, and haloperidol in rhesus monkeys depleted of caudate dopamine by repeated administration of d-methylamphetamine , 2004, Psychopharmacology.

[77]  S J Kish,et al.  Heterogeneous subregional binding patterns of 3H-WIN 35,428 and 3H-GBR 12,935 are differentially regulated by chronic cocaine self- administration , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[78]  M. Vogt,et al.  The effect of drugs on the amounts of substance P and 5‐hydroxytryptamine in mammalian brain , 1956, The Journal of physiology.

[79]  M. Iyo,et al.  Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. , 2001, The American journal of psychiatry.

[80]  S. Kubo,et al.  Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users , 2007, International Journal of Legal Medicine.

[81]  H. Higuchi,et al.  EFFECTS OF METHAMPHETAMINE AND COCAINE ON THE DEPLETION OF CATECHOLAMINE OF THE BRAIN, HEART AND ADRENAL GLAND IN RABBIT BY RESERPINE , 1962 .